Olaparib + Ceralasertib
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteosarcoma
Conditions
Osteosarcoma, Osteosarcoma Recurrent
Trial Timeline
Nov 24, 2020 → Jun 1, 2026
NCT ID
NCT04417062About Olaparib + Ceralasertib
Olaparib + Ceralasertib is a phase 2 stage product being developed by AstraZeneca for Osteosarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT04417062. Target conditions include Osteosarcoma, Osteosarcoma Recurrent.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04417062 | Phase 2 | Active |
Competing Products
18 competing products in Osteosarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Azenosertib + Gemcitabine | Zentalis Pharmaceuticals | Phase 1/2 | 33 |
| Lenvatinib + Ifosfamide + Etoposide + Lenvatinib | Eisai | Phase 2 | 52 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 2 | 52 |
| Camrelizumab in Combination With Neoadjuvant Chemotherapy | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Apatinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Saracatinib + Placebo | AstraZeneca | Phase 2 | 52 |
| robatumumab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| pazopanib | Novartis | Phase 2 | 52 |
| Avelumab | Pfizer | Phase 2 | 51 |
| Nivolumab + Azacitidine | Bristol Myers Squibb | Phase 1 | 32 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Cisplatin liposomal | Insmed | Phase 1/2 | 38 |
| Cabozantinib | Ipsen | Phase 2 | 49 |
| Sm-EDTMP | Jazz Pharmaceuticals | Phase 2 | 49 |
| LNTH2403 Phase 1 dose + Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). | Lantheus Holdings | Phase 1/2 | 38 |
| REOLYSIN® | Oncolytics Biotech | Phase 2 | 44 |